Hypertension and Vascular Disease Research Center and Department of Surgery, Wake Forest University School of Medicine, Winston Salem, North Carolina 27157, USA.
Am J Physiol Renal Physiol. 2010 Jun;298(6):F1297-305. doi: 10.1152/ajprenal.00110.2010. Epub 2010 Apr 7.
The study of experimental hypertension and the development of drugs with selective inhibitory effects on the enzymes and receptors constituting the components of the circulating and tissue renin-angiotensin systems have led to newer concepts of how this system participates in both physiology and pathology. Over the last decade, a renewed emphasis on understanding the role of angiotensin-(1-7) and angiotensin-converting enzyme 2 in the regulation of blood pressure and renal function has shed new light on the complexity of the mechanisms by which these components of the renin angiotensin system act in the heart and in the kidneys to exert a negative regulatory influence on angiotensin converting enzyme and angiotensin II. The vasodepressor axis composed of angiotensin-(1-7)/angiotensin-converting enzyme 2/mas receptor emerges as a site for therapeutic interventions within the renin-angiotensin system. This review summarizes the evolving knowledge of the counterregulatory arm of the renin-angiotensin system in the control of nephron function and renal disease.
实验性高血压的研究以及具有选择性抑制作用的药物的开发,这些药物作用于构成循环和组织肾素-血管紧张素系统成分的酶和受体,这导致了关于该系统如何参与生理和病理的新概念。在过去的十年中,人们重新强调了理解血管紧张素-(1-7)和血管紧张素转换酶 2 在调节血压和肾功能中的作用,这为肾素血管紧张素系统的这些成分在心脏和肾脏中发挥作用的机制的复杂性提供了新的认识,这些机制对血管紧张素转换酶和血管紧张素 II 产生负调节影响。由血管紧张素-(1-7)/血管紧张素转换酶 2/mas 受体组成的血管舒张轴作为肾素-血管紧张素系统内治疗干预的部位出现。这篇综述总结了肾素-血管紧张素系统中抗调节臂在控制肾单位功能和肾脏疾病中的不断发展的知识。